These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 703670

  • 1. [A contribution as to the effect of (+)-Cyanidanol-3 in chronic liver disease (author's transl)].
    Sondern W, Leube G.
    Med Klin; 1978 Oct 13; 73(41):1432-6. PubMed ID: 703670
    [Abstract] [Full Text] [Related]

  • 2. [Treatment of chronic diseases of the liver with catergen].
    Loginov AS, Dzhalalov KD, Blok IuE, Bendikov EA, Ausheva LKh.
    Ter Arkh; 1986 Oct 13; 58(2):73-6. PubMed ID: 3704945
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of (+)-cyanidanol-3 on chronic liver injury.
    Kovách G, Salamon F.
    Acta Physiol Hung; 1984 Oct 13; 64(3-4):443-8. PubMed ID: 6152368
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical, enzymological and histological changes in chronic diffuse liver diseases following (+)-cyanidanol-3 (Catergen) treatment.
    Halmy L, Dávid K, Nagy I, Stotz G, Kelemen JT.
    Acta Physiol Hung; 1984 Oct 13; 64(3-4):461-70. PubMed ID: 6152370
    [Abstract] [Full Text] [Related]

  • 8. [Influence of (+)-cyanidanol-3 on the course of acute viral hepatitis (author's transl)].
    Vido I, Schmidt FW, Müller R, Ranft U, Wildhirt E, Holzer E, Wallnöfer H, Korb G.
    Dtsch Med Wochenschr; 1980 Mar 07; 105(10):330-2. PubMed ID: 6153953
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [A new therapy of hepatic insufficiency. Experiments with (+)-3--cyanidanol. Its importance in the treatment of alcoholic hepatitis].
    Traissac FJ, Borg R.
    Minerva Dietol Gastroenterol; 1977 Mar 07; 23(3):237-42. PubMed ID: 372845
    [No Abstract] [Full Text] [Related]

  • 12. [What is certain in the therapy of hepatocellular diseases with cyanidanol?].
    Schomerus H.
    Internist (Berl); 1983 Dec 07; 24(12):684-9. PubMed ID: 6363332
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. (+)-Cyanidanol-3 for alcoholic liver disease: results of a six-month clinical trial.
    World MJ, Aps EJ, Shaw GK, Thomson AD.
    Alcohol Alcohol; 1984 Dec 07; 19(1):23-9. PubMed ID: 6149758
    [Abstract] [Full Text] [Related]

  • 15. [Study of therapy in chronic liver diseases. Double-blind study with cianidanol].
    Machalke K, Müller B.
    Fortschr Med; 1982 Apr 15; 100(14):665-7. PubMed ID: 6123478
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Enzymologic evaluation of the effectiveness of the hepatotropic drug catergen in chronic liver diseases].
    Tamarkina AD, Neverov IV, Turitsyna IG, Dement'eva ES, Krylova NI.
    Sov Med; 1985 Apr 15; (12):26-30. PubMed ID: 4095626
    [No Abstract] [Full Text] [Related]

  • 18. (+)-cyanidanol-3.
    Lancet; 1982 Mar 06; 1(8271):549. PubMed ID: 6120400
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cyanidanol: will a hepatotrophic drug from Europe go west?
    Hepatology; 1983 Mar 06; 3(1):121-3. PubMed ID: 6822375
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.